Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. (2017)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-017-01385-8
PubMed Identifier: 29123084
Publication URI: http://europepmc.org/abstract/MED/29123084
Type: Journal Article/Review
Volume: 8
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723